Cambridge Healthtech Institute’s 2nd Annual
Small Molecules for Cancer Immunotherapy
( 癌症免疫疗法的小分子药物 )
First-generation cancer immunotherapy agents being developed or approved are engineered T cells targeting tumors or mostly antibody-based biologics that target the immune checkpoint cascade. The success of these biologics in the clinic is now inspiring the discovery and development of small molecules that act on intracellular targets affecting immuno-modulatory pathways in cancer. Cambridge Healthtech Institute’s 2nd Annual Small Molecules for Cancer Immunotherapy conference brings together discovery chemists and biologists to talk about these new intracellular oncology targets and immuno-modulatory small molecule inhibitors that are being developed to act alone or in combination with existing treatments.
Who should attend: SCIENTISTS and EXECUTIVES from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in target ID & validation, discovery biology, cancer biology, immunology, discovery chemistry, biochemistry, molecular & cell biology, phenotypic screening, assay development, chemical biology, and other areas related to early drug discovery & development.
Coverage will include, but is not limited to:
- Development of small molecule immuno-oncology drugs for targeted therapies
- Emerging immune-oncology targets for small molecule inhibitors: immune checkpoint proteins, kinases, cytokines, non-kinase enzymes, ubiquitin, bromodomains, Toll-like receptors, chemokine receptors, nuclear receptors and more
- Update on preclinical and clinical development targeting IDO1, TDO, DUBs, USP7, PSMA, TIM3, VISTA, ARG1/2, A2A/B, CXCR1/2, CXCR4, CCR2, CCR5, TLR 4/7/8/9, FAK, ALK5, BRAF, CSF1, PI3K, IRAK4, CD38, TNFR2, STING, etc.
- Design of novel treatment combinations using small molecules with engineered T cells and checkpoint blocking antibodies
- Development of new molecular class of small molecules such as synthetic antibody mimics